Moors & Cabot, Inc. Tg Therapeutics, Inc. Transaction History
Moors & Cabot, Inc.
- $2.02 Billion
- Q4 2024
Shares
1 transactions
Others Institutions Holding TGTX
# of Institutions
375Shares Held
85.5MCall Options Held
3.78MPut Options Held
3M-
Vanguard Group Inc Valley Forge, PA15.6MShares$599 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$437 Million0.0% of portfolio
-
State Street Corp Boston, MA9.2MShares$353 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA3.19MShares$123 Million0.01% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V82.79MShares$107 Million0.09% of portfolio
About TG THERAPEUTICS, INC.
- Ticker TGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 145,274,000
- Market Cap $5.58B
- Description
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...